Modern pathologists have been challenged to “validate” mouse models of human cancer. Validation requires matching of morphological attributes of the model to human disease. Computers can assist in the validation process. However, adequate controlled, computer-readable vocabularies that can match terms do not currently exist in mouse pathology. Further, current standard diagnostic terminologies do not include the new concepts discussed here such as pathway pathology and mammary intraepithelial neoplasia. The terminologies must be revised and improved to meet the challenge. Human medicine has traditionally used “guilt-by-association” to validate interpretations of disease. Experimental pathology uses experimental verification exemplified by “test-by-transplantation.” Genetically Engineered Mice (GEM) develop unique tumor phenotypes bringing new structural-functional insights and reevaluation of concepts. Novel GEM-related tumors appear in all organ systems but mouse models of human breast cancer are prototypes. For example, mammary tumors induced by Mouse Mammary Tumor Virus (MMTV), chemical, radiation or other carcinogenic stimuli have limited phenotypes. These “spontaneous” or induced mammary tumors have never resembled human breast cancers. GEM tumors created with genes associated with human cancer are strikingly different. GEM tumors have unique histological phenotypes. Depending on the genes, the tumors may: 1) resemble MMTV-induced tumors, 2) display “signature” phenotypes, and 3) mimic human breast cancers. The phenotypes can be placed into structural and functional clusters with shared characteristics leading to the concepts of Pathway Pathology: tumor phenotype reflects the genotype.
Aldaz, C.M., Hu, Y., Daniel, R., Gaddis, S., Kittrell, F., and Medina, D. (2002). Serial analysis of gene expression in normal p53 null mammary epithelium. Oncogene21, 6366—76.
2.
Baader, F., Calvanese, D., McGuinness, D., Nardi, D., and Patel-Schneider, P. (2003). The Description Logic Handbook: Theory, Implementation and Application. Cambridge University Press, London.
3.
Buckhaults, P., Zhang, Z., Chen, Y.C., Wang, T.L., St. Croix, B., Saha, S., Bardelli, A., Morin, P.J., Polyak, K., Hruban, R.H., Velculescu, V.E., and Shih Ie, M. (2003). Identifying tumor origin using a gene expression-based classification map. Cancer Res63, 4144—9.
4.
Cardiff, R.D. (1984). Protoneoplasia: the molecular biology of murine mammary hyperplasia. Adv Cancer Res42, 167—90.
5.
Cardiff, R.D., Anver, M.R., Gusterson, B.A., Hennighausen, L., Jensen, R.A., Merino, M.J., Rehm, S., Russo, J., Tavassoli, F.A., Wakefield, L.M., Ward, J.M., and Green, J.E. (2000). The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting . Oncogene19, 968—88.
6.
Cardiff, R.D., Bern, H.A., Faulkin, L.J., Daniel, C.W., Smith, G.H., Young, L.J., Medina, D., Gardner, M.B., Wellings, S.R., Shyamala, G., Guzman, R.C., Rajkumar, L., Yang, J., Thordarson, G., Nandi, S., MacLeod, C.L., Oshima, R.G., Man, A.K., Sawai, E.T., Gregg, J.P., Cheung, A.T., and Lau, D.H. (2002). Contributions of mouse biology to breast cancer research. Comp Med52, 12—31.
7.
Cardiff, R.D., Moghanaki, D., and Jensen, R.A. (2001). Genetically Engineered Mouse Models of Mammary Intraepithelial Neoplasia. J Mamm Gland Biol Neoplasia5, 421—37.
8.
Cardiff, R.D., Sinn, E., Muller, W., and Leder, P. (1991). Transgenic oncogene mice. Tumor phenotype predicts genotype. Am J Pathol139, 495—501.
9.
Chen, H. (1994). Collaborative Systems: Solving the Vocabulary Problem. IEEE Computer27, 58—66.
10.
Daniel, C.W., De Ome, K.B., Young, J.T., Blair, P.B., and Faulkin, L.J., Jr. (1968). The in vivo life span of normal and preneoplastic mouse mammary glands: a serial transplantation study. Proc Natl Acad Sci USA61, 53—60.
11.
Dankort, D., Maslikowski, B., Warner, N., Kanno, N., Kim, H., Wang, Z., Moran, M.F., Oshima, R.G., Cardiff, R.D., and Muller, W.J. (2001). Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol Cell Biol21, 1540—51.
12.
Diaz-Cano, S.J., Blanes, A., and Wolfe, H.J. (2001). PCR techniques for clonality assays. Diagn Mol Pathol10, 24—33.
13.
DiGiovanna, M.P., Lerman, M.A., Coffey, R.J., Muller, W.J., Cardiff, R.D., and Stern, D.F. (1998). Active signaling by Neu in transgenic mice. Oncogene17, 1877—84.
14.
Faulkin, L.J., and DeOme, K.B. (1960). Regulation of growth and spacing of gland elements in the mammary fat pad of the C3H mouse. J Nat Cancer Inst24, 953—69.
15.
Fujii, H., Marsh, C., Cairns, P., Sidransky, D., and Gabrielson, E. (1996). Genetic divergence in the clonal evolution of breast cancer. Cancer Res56, 1493—7.
16.
Greene, F.L. (2002). American Joint Committee on Cancer and American Cancer Society: AJCC Cancer Staging Manual. Springer, New York.
17.
Guarino, N. (1995). Formal ontology, conceptual analysis and knowledge representation. Int J Human-Computer Stud43, 625—40.
18.
Guy, C.T., Cardiff, R.D., and Muller, W.J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol12, 954—61.
19.
Karayiannakis, A.J., Nakopoulou, L., Gakiopoulou, H., Keramopoulos, A., Davaris, P.S., and Pignatelli, M. (2001). Expression patterns of beta-catenin in in situ and invasive breast cancer. Eur J Surg Oncol27, 31—6.
20.
Katoh, M. (2001). Molecular cloning and characterization of human WNT3. Int J Oncol19, 977—82.
21.
Kinzler, K.W., and Vogelstein, B. (1996). Lessons from hereditary colorectal cancer. Cell87, 159—70.
22.
Landesman-Bollag, E., Song, D.H., Romieu-Mourez, R., Sussman, D.J., Cardiff, R.D., Sonenshein, G.E., and Seldin, D.C. (2001). Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem227, 153—65.
23.
Lejeune, S., Huguet, E.L., Hamby, A., Poulsom, R., and Harris, A.L. (1995). Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res1, 215—22.
24.
Lennington, W.J., Jensen, R.A., Dalton, L.W., and Page, D.L. (1994). Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer73, 118—24.
25.
Ma, X.J., Salunga, R., Tuggle, J.T., Gaudet, J., Enright, E., McQuary, P., Payette, T., Pistone, M., Stecker, K., Zhang, B.M., Zhou, Y.X., Varnholt, H., Smith, B., Gadd, M., Chatfield, E., Kessler, J., Baer, T.M., Erlander, M.G., and Sgroi, D.C. (2003). Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA100, 5974—9.
26.
Maglione, J.E., Moghanaki, D., Young, L.J., Manner, C.K., Ellies, L.G., Joseph, S.O., Nicholson, B., Cardiff, R.D., and MacLeod, C.L. (2001). Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res61, 8298—305.
27.
Michaelson, J.S., and Leder, P. (2001). Beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene20, 5093—9.
28.
Miyoshi, K., Rosner, A., Nozawa, M., Byrd, C., Morgan, F., Landesman-Bollag, E., Xu, X., Seldin, D.C., Schmidt, E.V., Taketo, M.M., Robinson, G.W., Cardiff, R.D., and Hennighausen, L. (2002). Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene21, 5548—56.
29.
Moser, A.R., Mattes, E.M., Dove, W.F., Lindstrom, M.J., Haag, J.D., and Gould, M.N. (1993). ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci USA90, 8977—81.
30.
Muthuswamy, S.K., and Muller, W.J. (1994). Activation of the Src family of tyrosine kinases in mammary tumorigenesis. Adv Cancer Res64, 111—23.
31.
Nandi, S., and McGrath, C.M. (1973). Mammary Neoplasia in Mice. Adv Cancer Res17, 353—414.
32.
Nusse, R., Theunissen, H., Wagenaar, E., Rijsewijk, F., Gennissen, A., Otte, A., Schuuring, E., and van Ooyen, A. (1990). The Wnt-1 (int-1) oncogene promoter and its mechanism of activation by insertion of proviral DNA of the mouse mammary tumor virus . Mol Cell Biol10, 4170— 9.
33.
Page, D.L. (1991). Intraductal breast carcinoma. Review of a multicenter series of 350 cases. Tumori77, I.
34.
Page, D.L., Dupont, W.D., Rogers, L.W., and Landenberger, M. (1982). Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer49, 751—8.
35.
Page, D.L., and Lagios, M.D. (1994). Pathology and clinical evolution of ductal carcinoma in situ (DCIS) of the breast. Cancer Lett86, 1—4.
36.
Rauh, M.J., Blackmore, V., Andrechek, E.R., Tortorice, C.G., Daly, R., Lai, V.K., Pawson, T., Cardiff, R.D., Siegel, P.M., and Muller, W.J. (1999). Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein. Mol Cell Biol19, 8169—79.
37.
Rector, A.L., and Nowlan, W.A. (1994). The GALEN project. Comput Meth Programs Biomed45, 75—8.
38.
Rector, A.L., Rogers, J.E., and Pole, P. (1996). The GALEN High Level Ontology. Fourteenth International Congress of the European Federation for Medical Informatics. MIE, Copenhagen , Denmark.
39.
Rosner, A., Miyoshi, K., Landesman-Bollag, E., Xu, X., Seldin, D.C., Moser, A.R., MacLeod, C.L., Shyamala, G., Gillgrass, A.E., and Cardiff, R.D. (2002). Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol161, 1087—97.
40.
Rosse, C., and Mejino, J.L.V. (2003). A reference ontology for bioinformatics: The Foundational Model of Anatomy. J Biomed Inform36, 478—500.
41.
Sawyer, E.J., Hanby, A.M., Rowan, A.J., Gillett, C.E., Thomas, R.E., Poulsom, R., Lakhani, S.R., Ellis, I.O., Ellis, P., and Tomlinson, I.P. (2002). The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol196, 437—44.
42.
Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., and Press, M.F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244, 707—12.
43.
Spackman, K.A., Campbell, K.E., and Cote, R.A. (1997). SNOMED RT: a reference terminology for health care. Proc AMIA Annu Fall Symposium. College of American Pathologists (CAP), Northfield, IL.
44.
van de Vijver, M.J., Mooi, W.J., Wisman, P., Peterse, J.L., and Nusse, R. (1988). Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene2, 175—8.
45.
Wang, T.C., Cardiff, R.D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E.V. (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature369, 669—71.
46.
Warnberg, F., Bergh, J., Zack, M., and Holmberg, L. (2001). Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev10, 495—9.
47.
Webster, M.A., Cardiff, R.D., and Muller, W.J. (1995). Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene. ProcNatlAcad Sci USA92, 7849—53.
48.
Wellings, S.R., Jensen, H.M., and Marcum, R.G. (1975). An atlas of sub-gross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst55, 231—73.
